ONCOZENGE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.955 SEK | +2.20% |
|
+2.99% | +27.99% |
| 04-08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
| 04-04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 135.4 | 64.42 | 36.19 | 46.33 | - |
| Enterprise Value (EV) 1 | 135.4 | 35.28 | 36.19 | 43.33 | 43.33 |
| P/E ratio | -35 x | -1.38 x | -2.27 x | -5.82 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -27.7 x | -0.81 x | - | -5.42 x | - |
| EV / FCF | -13.4 x | -1.6 x | - | -4.81 x | - |
| FCF Yield | -7.48% | -62.6% | - | -20.8% | - |
| Price to Book | 1.69 x | 1.9 x | - | 4.35 x | 4.35 x |
| Nbr of stocks (in thousands) | 11,713 | 11,713 | 11,713 | 11,713 | - |
| Reference price 2 | 11.56 | 5.500 | 3.090 | 3.955 | 3.955 |
| Announcement Date | 15/02/22 | 14/02/23 | 15/02/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | - | -4.894 | -43.57 | - | -8 | - |
| EBIT 1 | - | -4.894 | -43.57 | - | -8 | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.894 | -43.57 | - | -8 | - |
| Net income 1 | -0.636 | -3.886 | -46.65 | -15.9 | -8 | - |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.1100 | -0.3300 | -3.980 | -1.360 | -0.6800 | - |
| Free Cash Flow 1 | - | -10.12 | -22.08 | - | -9 | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | - | 15/02/22 | 14/02/23 | 15/02/24 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 29.1 | - | 3 | 3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -10.1 | -22.1 | - | -9 | - |
| ROE (net income / shareholders' equity) | - | -7.09% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 6.860 | 2.900 | - | 0.9100 | 0.9100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 5.36 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | - | 15/02/22 | 14/02/23 | 15/02/24 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +27.99% | 4.27M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- ONCOZ Stock
- Financials OncoZenge AB
